Publications

Detailed Information

Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells

DC Field Value Language
dc.contributor.authorJang, Ji-Young-
dc.contributor.authorJeon, Yoon-Kyung-
dc.contributor.authorKim, Chul-Woo-
dc.date.accessioned2012-06-28T06:32:00Z-
dc.date.available2012-06-28T06:32:00Z-
dc.date.issued2010-07-23-
dc.identifier.citationBMC CANCER; Vol.10 ; 391ko_KR
dc.identifier.issn1471-2407-
dc.identifier.urihttps://hdl.handle.net/10371/77787-
dc.description.abstractBackground: In breast cancer, the HER2/neu oncoprotein, which belongs to the epidermal growth factor receptor family, may trigger activation of the phosphoinositide-3 kinase (PI3K)/Akt pathway, which controls cell proliferation, survival, migration, and invasion. In this study, we examined the question of whether or not adenine nucleotide translocase 2 (ANT2) short hairpin RNA (shRNA)-mediated down-regulation of HER2/neu and inhibitory effects on the PI3K/Akt signaling pathway suppressed migration and invasiveness of breast cancer cells. Methods: We utilized an ANT2 vector-based RNA interference approach to inhibition of ANT2 expression, and the HER2/neu-overexpressing human breast cancer cell line, SK-BR3, was used throughout the study. Results: In this study, ANT2 shRNA decreased HER2/neu protein levels by promoting degradation of HER2/neu protein through dissociation from heat shock protein 90 (HSP90). As a result, ANT2 shRNA induced inhibitory effects on the PI3K/Akt signaling pathway. Inhibition of PI3K/Akt signaling by ANT2 shRNA caused down-regulation of membrane-type 1 matrix metalloproteinase (MT1-MMP) and vascular endothelial growth factor (VEGF) expression, decreased matrix metalloproteinase 2 (MMP2) and MMP9 activity, and suppressed migration and invasion of breast cancer cells. Conclusions: These results indicate that knock-down of ANT2 by shRNA down-regulates HER2/neu through suppression of HSP90`s function and inhibits the PI3K/Akt signaling pathway, resulting ultimately in suppressed migration and invasion of breast cancer cells.ko_KR
dc.language.isoenko_KR
dc.publisherBIOMED CENTRAL LTDko_KR
dc.titleDegradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cellsko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor장지영-
dc.contributor.AlternativeAuthor전윤경-
dc.contributor.AlternativeAuthor김철우-
dc.identifier.doi10.1186/1471-2407-10-391-
dc.citation.journaltitleBMC CANCER-
dc.description.citedreferenceWang S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-81-
dc.description.citedreferenceMAHMUT Y, 2009, CANC METASTASIS REV, V28, P15-
dc.description.citedreferenceJang JY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1857-
dc.description.citedreferenceOno M, 2006, CLIN CANCER RES, V12, P7242, DOI 10.1158/1078-0432.CCR-06-0646-
dc.description.citedreferenceStirling PC, 2006, NAT STRUCT MOL BIOL, V13, P865, DOI 10.1038/nsmb1153-
dc.description.citedreferenceLe Bras M, 2006, CANCER RES, V66, P9143, DOI 10.1158/0008-5472.CAN-05-4407-
dc.description.citedreferenceScaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-06-1554-
dc.description.citedreferenceERIC I, 2006, AM J PHYSIOL-CELL PH, V291, P579-
dc.description.citedreferenceRomond EH, 2005, NEW ENGL J MED, V353, P1673-
dc.description.citedreferencePiccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659-
dc.description.citedreferenceChevrollier A, 2005, J BIOENERG BIOMEMBR, V37, P307, DOI 10.1007/s10863-005-8642-5-
dc.description.citedreferenceMeares GP, 2004, FEBS LETT, V574, P181, DOI 10.1016/j.febslet.2004.08.026-
dc.description.citedreferenceSreedhar AS, 2004, FEBS LETT, V562, P11-
dc.description.citedreferenceCitri A, 2004, CELL CYCLE, V3, P51-
dc.description.citedreferenceLuciakova K, 2003, J BIOL CHEM, V278, P30624, DOI 10.1074/jbc.M303530200-
dc.description.citedreferenceRao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121-
dc.description.citedreferenceVal JFF, 2002, CANCER GENET CYTOGEN, V138, P69-
dc.description.citedreferenceGARCIARUIZ C, 2002, J BIOL CHEM, V277, P16396-
dc.description.citedreferenceSlamon DJ, 2001, NEW ENGL J MED, V344, P783-
dc.description.citedreferencePrenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11-
dc.description.citedreferenceBraun S, 2001, CANCER RES, V61, P1890-
dc.description.citedreferenceXu WP, 2001, J BIOL CHEM, V276, P3702-
dc.description.citedreferenceSternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463-
dc.description.citedreferenceGreenlee RT, 2001, CA-CANCER J CLIN, V51, P15-
dc.description.citedreferenceFang JM, 2000, P NATL ACAD SCI USA, V97, P3884-
dc.description.citedreferenceClynes RA, 2000, NAT MED, V6, P443-
dc.description.citedreferenceZhou BP, 2000, J BIOL CHEM, V275, P8027-
dc.description.citedreferenceMenard S, 2000, J CELL PHYSIOL, V182, P150-
dc.description.citedreferenceCobleigh MA, 1999, J CLIN ONCOL, V17, P2639-
dc.description.citedreferencePegram MD, 1998, J CLIN ONCOL, V16, P2659-
dc.description.citedreferenceFiore C, 1998, BIOCHIMIE, V80, P137-
dc.description.citedreferenceWOLFGANG HS, 1998, J CELL BIOL, V143, P901-
dc.description.citedreferenceWerb Z, 1997, CELL, V91, P439-
dc.description.citedreferenceBaselga J, 1996, J CLIN ONCOL, V14, P737-
dc.description.citedreferenceCORNELIUS LA, 1995, J INVEST DERMATOL, V105, P170-
dc.description.citedreferenceHANEMAAIJER R, 1993, BIOCHEM J, V296, P803-
dc.description.citedreferenceUNEMORI EN, 1990, J BIOL CHEM, V265, P445-
dc.description.citedreferenceMIGNATTI P, 1989, J CELL BIOL, V108, P671-
dc.description.citedreferenceSLAMON DJ, 1987, SCIENCE, V235, P177-
dc.description.tc2-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share